Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
This article was originally published in The Pink Sheet Daily
Fueled by the Chinese government's latest five-year plan, which aims to promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth.
You may also be interested in...
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.